Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002105 · ClinicalTrials.gov registry record · Phase 3

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

A Phase 3 study of HIV Infections and Sarcoma, Kaposi, sponsored by Sequus Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
220
Enrollment target
4
Study locations

NCT00002105: Completed Phase 3 study of HIV Infections and Sarcoma, Kaposi, sponsored by Sequus Pharmaceuticals.

NCT00002105 is a Phase 3 study of HIV Infections and Sarcoma, Kaposi that has completed, run by Sequus Pharmaceuticals. The registered enrollment target is 220 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002105, a Phase 3 study of HIV Infections and Sarcoma, Kaposi, has completed, sponsored by Sequus Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
220 participants
Enrollment target
4
Study locations

Study Summary

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.

Conditions Studied

HIV Infections Sarcoma, Kaposi

Interventions

  • DRUG Doxorubicin hydrochloride (liposomal)
  • DRUG Bleomycin sulfate
  • DRUG Vincristine sulfate

Study Locations (4)

Massachusetts

  • Beth Israel Hosp - Boston

New York

  • Mount Sinai Med Ctr - New York

Texas

  • Twelve Oaks Hosp - Houston

Washington

  • Virginia Mason Research Center / Clinical Trial Unit - Seattle

Trial Details

FieldValue
Enrollment Target 220 participants
Phase Phase 3
Sequus Pharmaceuticals

3 total trials

What the finished NCT00002105 record still lists

NCT00002105 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (51% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin hydrochloride (liposomal) is the first listed.

NCT00002105 reports a single indexed study location in Massachusetts, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT00002105 about?

NCT00002105 is a clinical study titled "Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma". To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a popula...

What is the current status of trial NCT00002105?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants.

What conditions does trial NCT00002105 study?

This clinical trial studies the following conditions: HIV Infections, Sarcoma, Kaposi.

What interventions are being tested in trial NCT00002105?

The interventions under investigation include: Doxorubicin hydrochloride (liposomal) (DRUG), Bleomycin sulfate (DRUG), Vincristine sulfate (DRUG).

Who is sponsoring clinical trial NCT00002105?

This trial is sponsored by Sequus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002105 being conducted?

This trial has 4 study locations across Massachusetts, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002105's enrollment target sits among peer trials

220 158th of 542 higher than 383 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Related registry views

Source: ClinicalTrials.gov NCT00002105, the US trial registry maintained by the National Library of Medicine. NCT00002105 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.